BioSpace News Archive

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that Francois J. Lebel, M.D., Executive Vice President and Chief Medical Officer, will step down from his role to pursue other opportunities, effective immediately.

Moderna, Inc. and OriCiro Genomics K.K. today announced they have entered into a definitive agreement through which Moderna will acquire OriCiro for $85 million.

ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 11th at 3:00 p.m. PT.

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company today announced that the Company will participate in the J.P. Morgan 41st Annual Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. PT.

Context Therapeutics Inc. provided 2022 year-end updates and corporate guidance for 2023.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023.

Certara, Inc., announced it has acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software which allows life sciences organizations to perform predictions and answer complex questions across structured and unstructured bio-medical information.

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled “Methods and Compositions for Treating Diabetes.”

Elixirgen Therapeutics, Inc. announced that members of the management team will be attending the Biotech Showcase Conference taking place January 9-11, 2023 in San Francisco, California.

Tenax Therapeutics, Inc. announced that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20.